Biosimilar-Gedatolisib Combo Elicits Response in Resistant mBC
In metastatic breast cancer (mBC) resistant to multiple lines, Herzuma (a trastuzumab biosimilar) plus gedatolisib, an mTOR/PI3K signaling pathway inhibitor, demonstrated value.
Patient-Provider Surveys Elucidate Biosimilar Switching Process in Oncology
After a switch to a biosimilar, patients and their oncologists may not always agree on how well the switch was described or whether the patient felt involved.
Ontruzant Biosimilar Demonstrates Equivalence to Herceptin in 5-Year Study
The trial included "drifted" (nonstandard) reference product, forcing a stratified analysis to yield relevant data.
EirGenix Trastuzumab Biosimilar Candidate Demonstrates Equivalence in HER2-Positive Breast Cancer
A trastuzumab biosimilar candidate demonstrated equivalence to Herceptin in patients with early-stage human epidermal growth factor receptor 2 (HER2)–breast cancer.
The Top 5 Biosimilar Articles From SABCS 2020
Here are the top 5 biosimilar articles from SABCS 2020.
Data From HERITAGE Confirm PK Biosimilarity for Ogivri
Pharmacokinetic (PK) parameters matched up with those of reference trastuzumab in an extended analysis of data from the HERITAGE trial.
Investigators Chart ABP 980 Biosimilar Uptake in European Clinics
Among patients treated for metastatic breast cancer, 40% switched to ABP 980.
Investigators Demonstrate Dramatic Rise in Trastuzumab Biosimilar Use
In little over 1 year of use in patients with breast cancer, trastuzumab biosimilars have seen rapid growth in uptake.
Trastuzumab Biosimilar With PIK3CA Inhibitor Shows Efficacy in Advanced Breast Cancer
Two studies of trastuzumab biosimilars have improved understanding of these medicines as monotherapy and in combination with other agents in metastatic breast cancer.
Biosimilar Conjugate Evaluated in HER2-Positive Patient Population
Investigators explained the potential for durable antitumor efficacy in patients with human epidermal growth factor receptor 2 (HER2)-expressing or -driven tumors who have exhausted other treatment options.
Investigators Look to Cut Breast Cancer Recurrence With Posttrastuzumab Therapy
GP2 peptide/G-CSF in HER2-equivocal and -positive breast cancer has shown promise.
